Scarica l'app Stockscreener
3.79
0.53%
0.02
Dopo l'orario di chiusura:
3.79
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.77
Aprire:
$3.81
Volume 24 ore:
237.76K
Relative Volume:
1.52
Capitalizzazione di mercato:
$155.11M
Reddito:
$2.00M
Utile/perdita netta:
$109.16M
Rapporto P/E:
1.467
EPS:
2.5835
Flusso di cassa netto:
$-9.11M
1 W Prestazione:
+2.43%
1M Prestazione:
-18.32%
6M Prestazione:
+25.08%
1 anno Prestazione:
+75.46%
Intervallo 1D:
$3.765
$3.92
Intervallo di 1 settimana:
$3.70
$3.93
Portata 52W:
$1.975
$5.01
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Nome
Oramed Pharmaceuticals Inc
Settore
Industria
Telefono
646-844-1164
Indirizzo
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.79 | 157.16M | 2.00M | 109.16M | -9.11M | 2.5835 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-09 | Iniziato | National Securities | Buy |
| 2020-12-03 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-11 | Iniziato | Aegis Capital | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-12-11 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Reiterato | FBR Capital | Outperform |
| 2015-12-01 | Reiterato | H.C. Wainwright | Buy |
| 2015-11-19 | Iniziato | FBR Capital | Outperform |
| 2015-04-13 | Ripresa | MLV & Co | Buy |
| 2014-01-30 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Iniziato | MLV & Co | Buy |
| 2013-12-03 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Oramed Pharmaceuticals Inc Borsa (ORMP) Ultime notizie
June 2026 Penny Stocks To Watch For Potential Growth - Yahoo Finance
These healthcare stocks are combining strong gains with reasonable prices - MSN
Daily Brief Health Care: Parabilis Medicines, Integral Diagnostics, Healthequity Inc, ICON PLC, KT Medical Service, Leong Guan Holdings, Oramed Pharmaceuticals , Otsuka Holdings, Crism Therapeutics, TransCode Therapeutics and more - Smartkarma
Oramed Pharmaceuticals (ORMP) Faces Selling Pressure; Key Levels in FocusTriple Bottom - newsline.com
Oramed Pharmaceuticals Inc. (ORMP) Q4 2025 Earnings: Surprise Profitability on Milestone RevenueEarnings Expansion Phase - newsline.com
ORMP Should I Buy - Intellectia AI
Oramed Pharmaceuticals (ORMP) Holds Near Key Support Amid Modest DeclineDemand Zone - The Legal Advocate
Type 2 Diabetes Pipeline 2026: FDA Updates, Therapy - openPR.com
Oramed Pharmaceuticals (ORMP) Drops 8.9%: Support Level Under PressureNAAIM Exposure - The Legal Advocate
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction - Seeking Alpha
Oramed Pharmaceuticals (ORMP) Q4 2025 Results Meet Expectations — Revenue $N/AMargin Compression Risk - newsline.com
Oramed Pharmaceuticals Inc. Q1 2026 Financial Report: Key Investments, Marketable Securities, and Forward-Looking Statements - Minichart
Oramed: Q1 Earnings Snapshot - marketscreener.com
ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary - TradingView
Oramed (NASDAQ: ORMP) swings to $38.3M Q1 profit on Alpha Tau and Scilex gains - Stock Titan
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lifeward Ltd.16079622026 - SEC.gov
Oramed Pharmaceuticals (ORMP) Q4 2025 Financial OverviewIncome Pick - newser.com
Oramed Pharmaceuticals Delays Quarterly SEC Filing - TipRanks
Oramed Pharmaceuticals (NASDAQ: ORMP) notifies late Q1 2026 Form 10-Q filing - Stock Titan
About Us | Oil & Gas JournalOramed Pharmaceuticals Inc.Common Stock (Nasdaq:ORMP) Stock Quote - FinancialContent
Oramed Pharmaceuticals (ORMP) Stock: Slides -0.74%, Support at $4.46 2026-05-15Buy Signals - newser.com
Aquamarine reports 5.06% stake in Oramed (ORMP) via Schedule 13G - Stock Titan
Oramed Pharmaceuticals Discloses Investment at Lifeward with 49.9% Stake - TradingView
Oramed details Lifeward (LFWD) equity stake, notes and warrants - Stock Titan
Oramed (LFWD) reports 49.9% Lifeward stake, $9M notes and warrants - Stock Titan
Oramed Pharmaceuticals stock (US68403P1003): Oral drug delivery innovator for US diabetes market - AD HOC NEWS
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks - Yahoo Finance
Oramed Pharmaceuticals stock (US68403P1003): Shares surged 7.98% to $2.30 - AD HOC NEWS
TradingKey - TradingKey
MSN Money - MSN
ORMP News | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
NNDM stock in focus: Nano Dimension pops a poison pill days after Oramed stake build-up - MSN
ORMP (Oramed Pharmaceuticals) falls 2.84% after releasing Q4 2025 earnings with no prior analyst consensus estimates.Current Ratio - Xã Thanh Hà
ORMP (Oramed Pharmaceuticals Inc.) rises 0.53 percent following release of its 2025 fourth quarter earnings results.Debt/Equity - Xã Thanh Hà
Oramed Pharmaceuticals (ORMP) Stock Rally Stalls (+1.05%) 2026-04-16Shared Momentum Picks - Xã Vĩnh Công
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors - Yahoo Finance
Evolus and Oramed Pharmaceuticals Compared - National Today
Setup Watch: Is Oramed Pharmaceuticals Inc stock technically oversold2026 Opening Moves & Daily Profit Focused Stock Screening - baoquankhu1.vn
Oramed Pharmaceuticals Inc Azioni (ORMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oramed Pharmaceuticals Inc Azioni (ORMP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kidron Miriam | Chief Scientific Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
1,448,664 |
| Gabay Avraham | Chief Financial Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
649,256 |
| KIDRON NADAV | President and CEO |
Jan 22 '26 |
Option Exercise |
0.00 |
109,000 |
0 |
3,355,238 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):